Corona Remedies Q2 Revenue Up 22.2% to ₹441.2 Cr

Corona Remedies Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported a significant revenue growth of 22.2% year-on-year for Q2FY27, reaching ₹441.2 Cr (₹361.1 Cr in Q2FY26), and a 22.0% growth for H1FY27, with revenue at ₹863.6 Cr (₹707.7 Cr in H1FY26). Profit After Tax (PAT) for Q2FY27 was ₹60.7 Cr, a 27.5% increase from ₹47.6 Cr in Q2FY26. PAT margin stood at 13.7% for Q2FY27, compared to 13.2% in Q2FY26. The company highlighted outperforming the Indian Pharmaceutical Market (IPM) growth by 1.9 times and achieving strong volume growth, pricing power, and new introductions. Key business achievements include four brands exceeding ₹100 Cr in annual sales and receiving ANVISA GMP certification for its manufacturing facility. The company's chronic and semi-chronic business segments also showed robust growth.